Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1010396-29-8

Post Buying Request

1010396-29-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1010396-29-8 Usage

Description

S-23, the orally bioavailable nonsteroidal SARM, is appreciated by jocks over the world for its one of a kind capacity to improve fit bulk and bone tissue. A more secure option in contrast to anabolic steroid, this particular androgen receptor modulator is incredibly powerful to lose obstinate fat. Considered by numerous individuals as an amazing form of S-4 (Andarine), S-23 is a standout amongst other execution upgrading medications to solidify muscle and increase a grainier stylish look.

Uses

S 23 is a selective androgen receptor modulator.

benefits

Increments both skeletal and bulkAdvances durable bulk and perseverance gainsPerfect for muscle solidifyingTotally sets off catabolism in a calorie shortageBuilds bone quality and decreases fat massImproves drive in peopleEncourages clients to hold increases long after a cycleNo swelling or liquid maintenanceStep by step instructions to Use S-23

Biological Activity

S-23 is a selective androgen receptor modulator (SARM). It binds to the AR (Ki = 1.7 nM) and induces AR-mediated transcriptional activation in CV-1 cells expressing the human receptor when used at a concentration of 10 nM. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats. It decreases testicular sperm concentration without reducing mounting behavior or the number of intromissions in intact rats when administered in combination with estradiol benzoate (Item No. 10006487). S-23 (3 mg/kg) also increases preference for sexually active intact males when administered to ovariectomized female rats.

Clinical Use

S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.

Check Digit Verification of cas no

The CAS Registry Mumber 1010396-29-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,0,3,9 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1010396-29:
(9*1)+(8*0)+(7*1)+(6*0)+(5*3)+(4*9)+(3*6)+(2*2)+(1*9)=98
98 % 10 = 8
So 1010396-29-8 is a valid CAS Registry Number.

1010396-29-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (55939)  (S)-3-(4-Chloro-3-fluorophenoxy)-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-2-methylpropionamide  analytical standard

  • 1010396-29-8

  • 55939-25MG

  • 1,696.50CNY

  • Detail

1010396-29-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

1.2 Other means of identification

Product number -
Other names C-31

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1010396-29-8 SDS

1010396-29-8Synthetic route

4-chloro-3-fluorophenol
348-60-7

4-chloro-3-fluorophenol

(2R)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
206193-17-1

(2R)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

Conditions
ConditionsYield
Stage #1: (2R)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide With potassium carbonate for 2h; Reflux;
Stage #2: 4-chloro-3-fluorophenol With potassium carbonate In isopropyl alcohol for 3h; Reflux;
70.5%
With potassium carbonate In isopropyl alcohol for 3h; Reflux;70.5%
(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide
512776-95-3

(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide

4-chloro-3-fluorophenol
348-60-7

4-chloro-3-fluorophenol

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

Conditions
ConditionsYield
With potassium carbonate In butanone Reflux;
4-amino-2-trifluoromethylbenzonitrile
654-70-6

4-amino-2-trifluoromethylbenzonitrile

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: thionyl chloride / tetrahydrofuran / 3 h / 4 °C / Inert atmosphere
1.2: 20 °C
2.1: potassium carbonate / isopropyl alcohol / 3 h / Reflux
View Scheme
(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

N,N-Dimethylcarbamoyl chloride
79-44-7

N,N-Dimethylcarbamoyl chloride

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl dimethylcarbamate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl dimethylcarbamate

Conditions
ConditionsYield
Stage #1: (S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0℃;
Stage #2: N,N-Dimethylcarbamoyl chloride In N,N-dimethyl-formamide; mineral oil at 20℃;
155 g
(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

methanesulfonyl chloride
124-63-0

methanesulfonyl chloride

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl methanesulfonate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl methanesulfonate

Conditions
ConditionsYield
Stage #1: (S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide With sodium hydride In tetrahydrofuran; mineral oil at 0℃;
Stage #2: methanesulfonyl chloride In tetrahydrofuran; mineral oil at 20℃;
n-hexanoic anhydride
2051-49-2

n-hexanoic anhydride

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl pentanoate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl pentanoate

Conditions
ConditionsYield
In pyridine Reflux;70 g
(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

acetic anhydride
108-24-7

acetic anhydride

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl acetate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl acetate

Conditions
ConditionsYield
In pyridine Reflux;0.4 g
nicotinic anhydride
16837-38-0

nicotinic anhydride

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl pyridine-3-carboxylate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl pyridine-3-carboxylate

Conditions
ConditionsYield
In pyridine for 10h; Reflux;100 g
(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
1010396-29-8

(S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide

benzoic acid anhydride
93-97-0

benzoic acid anhydride

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl benzoate

(S)-1-(4-cyano-3-(trifluoromethyl)anilino)-3-(4-chloro-3-fluorophenoxyl)-2-methyl-1-oxopropyl benzoate

Conditions
ConditionsYield
In pyridine117 g

1010396-29-8Downstream Products

1010396-29-8Relevant articles and documents

METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

-

, (2016/05/10)

The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic-floor disorders by administering a SARM compound of the invention.

Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators

Bohl, Casey E.,Wu, Zengru,Chen, Jiyun,Mohler, Michael L.,Yang, Jun,Hwang, Dong Jin,Mustafa, Suni,Miller, Duane D.,Bell, Charles E.,Dalton, James T.

supporting information; experimental part, p. 5567 - 5570 (2009/06/30)

Selective androgen receptor modulators (SARMs) are essentially prostate sparing androgens, which provide therapeutic potential in osteoporosis, male hormone replacement, and muscle wasting. Herein we report crystal structures of the androgen receptor (AR) ligand-binding domain (LBD) complexed to a series of potent synthetic nonsteroidal SARMs with a substituted pendant arene referred to as the B-ring. We found that hydrophilic B-ring para-substituted analogs exhibit an additional region of hydrogen bonding not seen with steroidal compounds and that multiple halogen substitutions affect the B-ring conformation and aromatic interactions with Trp741. This information elucidates interactions important for high AR binding affinity and provides new insight for structure-based drug design.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1010396-29-8